Orphan medicines in the EU

On 28 February 2020 the EMA published the leaflet on orphan medicines in the EU.

The EU offers incentives to encourage companies to research and develop medicines for rare diseases that otherwise would not be developed. To access these incentives, companies can apply for orphan designation for their medicine, provided certain criteria are met.

Read the pdf
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /